Skip to main content

Life Sciences Patent Network (LSPN) North America Fall 2025

Oct
21
2025

Date: October 21, 2025

Location: Hyatt Regency, San Francisco

At this year's LSPN North America Fall 2025 conference, Mintz Members Terri Shieh-Newton and Siegmund Gutman will be speaking on different panels. 

Terri Shieh-Newton panel is titled "Integrating Data Rights and IP: Mitigating Reach-Through Risks." This session will examine how life sciences companies leveraging AI can develop comprehensive IP strategies that reduce reach-through risks by integrating patents, trade secrets, and data rights licenses. The discussion will highlight the benefits of bundling these protections effectively, the need to align IP safeguards with the company’s business model, and the implications of negotiating data rights licenses. It will also emphasize the importance of proactively building IP strategies to prepare for potential disputes.

Siegmund Gutman's panel is speak on a panel titled “Unlocking Value Through Method-of-Manufacture Patents: Strategic Litigation and Patent Claiming Considerations.” This session will explore how method of manufacture patents can be strategically structured and leveraged, especially in biologics and small molecules, to block infringing imports, enhance enforcement, including through the ITC, and complement trade secret protection for life sciences companies that are shifting manufacturing abroad.

Register for Event

Speakers

Terri Shieh-Newton, PhD, is a Mintz Member who guides clients on portfolio management and landscape analysis. She's a trained immunologist with a PhD in Cellular and Molecular Medicine, and she works with companies of all sizes in a wide range of life sciences and clean technology industries.
Siegmund Gutman

Siegmund Gutman

Speaker

Siegmund Y. (“Sige”) Gutman is a nationally recognized patent litigator and counselor who serves as Chair of Mintz’s Life Sciences Litigation Practice and Co-chair of the firm’s Patent Litigation Practice. Drawing on his background and industry experience in molecular and cell biology and biophysical chemistry, Sige litigates cases involving biologic drug patents, life sciences innovations, and the Hatch-Waxman Act. He also develops and executes market exclusivity and freedom to operate strategies and handles inter partes patent office actions.